G
Galimedix Therapeutics, Inc.
Profile managed by Bizz IdGalimedix Therapeutics
Estados Unidos
1-10 employees
Description
Phase 2 clinical-stage biopharmaceutical company developing innovative treatments for neurodegenerative eye diseases such as dry age-related macular degeneration (AMD) and glaucoma, with candidate GAL-101 in partnership with Théa Open Innovation.